New Venturetec AG - IPO Road Show Presentation Osiris Therapeutics - 500 Beiträge pro Seite

[Charly_2]

IPO Road Show Presentation Osiris Therapeutics

http://www.osiristx.com/news2.php?id=38

..dies wird der Beteiligungsgesellschaft New Venturetec mehrere 100 Mio CHF in die Kasse spülen

Osiris ist alleiniger Weltmarkführer auf ihrem Fachgebiet der Stammzellenanwendung bei Erwachsenen.

http://www.osiristx.com/

Osiris Therapeutics will hold an IPO Road Show Presentation on Wednesday, July 19, 2006, from 12.00 to 13.30 at the Park Hyatt, Beethovenstrasse 21, 8022 Zurich.

If you wish to participate on this presentation please kindly replay to this email.

If you wish a one-on-one meeting with the management of Osiris please contact us.

Sincerely

Peter Friedli

************************
Peter Friedli
Friedli Corporate Finance
Freigutstrasse 5
8002 Zürich
Switzerland
Tel: [phone]
Fax: [phone]
Email: [e-mail]
Internet: www.newventuretec.com,
www.inventureltd.com

[TheCrane]

Antwort auf Beitrag Nr.: 22.584.946 von Charly_2 am 14.07.06 10:09:04

Es wird davon ausgegangen, dass die Firma ca. 50-60 Millionen Franken einnimmt.

Die Firma (amerikanisch) gehört zu 80 % schweizer Investoren.

Positiv ist auch, dass die Firma Stammzellen aus dem Knochenmark gewinnen kann, da die Verwendung von Embryonen heftigst umstritten ist in den USA.

Leider ist der Termin für den Startschuss noch nicht bekannt.

[Gulliver]

der verkaufsprospekt von osiris ist draußen:

http://www.sec.gov/Archives/edgar/data/1360886/0001047469060…


die jungs wollen 3,5 millionen shares zwischen 11 und 13 $ raushauen, außerdem gibts nen greenshoe von 500k.

die investmentbanken würde der company bei erfolgreichem ipo damit eine cap von 300 bis 380 millionen $ zugestehen.

Osiris gehört mit Sicherheit zu den besseren Werten in diesem Sektor, dennoch würde ich CYTX eindeutig bevorzugen

cu gulliver

[Charly_2]

Antwort auf Beitrag Nr.: 23.038.621 von Gulliver am 25.07.06 13:57:52

http://board.cash.ch/bb/viewtopic.php?t=110

Charly

[Gulliver]

Antwort auf Beitrag Nr.: 23.067.939 von Charly_2 am 26.07.06 17:58:45

ich wußte gar nicht, dass "hans" mein alter ego ist

wer etwas tiefer ins stammzellenresearch einsteigen möchte...

http://www.xn--junge-fchse-zhb.de/ResearchWriteUpCytorithera…

cu gulliver

[Gulliver]

AP
IPO Spotlight: Osiris Therapeutics
Friday July 28, 4:11 pm ET
By Wallace Witkowski, AP Business Writer
Osiris Therapeutics Plans Public Debut Into Volatile Stem Cell Biotech Market

NEW YORK (AP) -- Amid the recent controversy surrounding stem cell research, Osiris Therapeutics Inc. plans to join the small cadre of publicly traded biotech companies developing treatments using the technology, setting itself apart as the only company with a stem cell treatment on the U.S. market.

ADVERTISEMENT
However, the Baltimore-based biotech company enters a challenging market for stem cell companies, in which stock prices tend to get worse before they get better.

Last week, Osiris said in a filing with the Securities and Exchange Commission it will sell 3.5 million shares at $11 to $13 apiece in its initial public offering, slated for July 31. An additional 525,000 shares will be made available to underwriters for overallotments. Jefferies & Co. is the lead bookrunning manager and Lazard Capital Markets is acting as co-lead manager.

In the company's original May registration statement, Osiris filed to sell up to $80 million of its shares. Under the amended registration, the company would only sell $38.5 million to $45.5 million worth of shares.

So far this year, eight biotech companies have launched IPOs, and seven others filed proposals.

Rich Peterson, a research analyst with Thomson Financial, said biotech stocks that have debuted this year are off an average of 9 percent, while stocks that debuted last year are off an average of 3 percent from their initial price.

"In general biotech IPOs are hard pressed," said Peterson in an interview. "It's the nature of business: they generally don't have established products, and are hoping to hit it big."

On the whole, Peterson said the year has been pretty flat for IPOs, with notable successes like J. Crew and Chipolte balanced by disappointments like Vonage.

In its latest filing, Osiris sets itself apart from competitors by saying it sells the only commercially available product in the United States containing viable stem cells. The product, Osteocel, is used to regenerate bone. Launched in July 2005, Osiris booked Osteocel sales of $957,000 in 2005, and $1.1 million in the quarter ended March 31. Osiris uses stem cells harvested from adult bone marrow.

The business plans to develop products that prevent the rejection of bone marrow transplants in cancer patients, heal heart tissue after a heart attack, and regenerate tissue following knee injuries to prevent arthritis. The company has a strategic alliance with medical device maker Boston Scientific Corp. for the heart application.

Founded in 1992, the company said in its filing it has spent $147.7 million to date and expects losses to continue "for at least the next several years." In 2005, the company posted a loss of $20 million, and recorded a loss of $5.1 million in the quarter ended March 31.

Currently, Osiris Chairman Peter Friedli owns 54 percent of shares and Swiss investment firm Venturetec Inc., where Friedli acts as president, owns 13 percent. After the offering, Friedli will own 48 percent of the company, and Venturetec will hold 12 percent of the roughly 27 million outstanding shares.

Osiris plans to use proceeds for research and development, general corporate purposes, and possibly to prepay principal and interest on a promissory note.

The company has three products in development: Prochymal for bone marrow transplant use, Provacel for repairing heart tissue, and Chondrogen for regenerating knee cartilage.

Prochymal is the farthest along, and is about to enter late-stage clinical trials. Prochymal is designated an orphan drug with a fast-track review by the Food and Drug Administration, meaning that the company can submit data as it becomes available -- rather than having to wait to submit it all at once -- and that the drug will receive seven years of marketing exclusivity if approved.

In April, the company completed enrollment for an early-to-mid-stage clinical trial for Chondrogen, and an early-stage clinical trial for Provacel.

Compared with those of their larger biotech counterparts, stock prices of smaller stem cell technology companies have steadily drifted toward 52-week lows in the past year. Publicly traded companies include StemCells Inc., Aastrom Biosciences Inc., ViaCell Inc. and Geron Corp., the only publicly traded company to use embryonic stem cells in research.

In comparison, the American Stock Exchange's Biotechnology Index, which follows 20 biotech companies, is up about 4 percent from a year ago.

Stem cells extracted from embryos are controversial because the embryos are destroyed in the process. Last week, President Bush used the first veto of his presidency to block a bill to allow more federal funding for embryonic stem cell research. Congress did not produce enough votes to overturn the veto.

Osiris plans to trade on the Nasdaq under the ticker symbol "OSIR."

[Gulliver]

Antwort auf Beitrag Nr.: 23.220.920 von Gulliver am 30.07.06 00:08:13

Osiris Announces Pricing of Its Initial Public Offering

August 4, 2006 – Baltimore, Maryland - Osiris Therapeutics, Inc. announced today the pricing of its initial public offering of 3,500,000 shares of its common stock at a price of $11.00 per share. All of the shares are being sold by the Company. Up to an additional 525,000 shares have been made available to the underwriters to cover over-allotments, if any. Osiris’ common stock is expected to begin trading on The NASDAQ Global Market on Friday August 4, 2006 under the symbol "OSIR."

The shares are being offered by an underwriting syndicate led by Jefferies and Company acting as the bookrunning manager with Lazard Capital Markets and Leerink Swann and Company acting as the Co-Lead and Co-Manager, respectively. This offering will be made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained from Jefferies and Company, 520 Madison Avenue, 12th Floor, New York, NY 10022 or by fax request at [phone].

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on August 3, 2006. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction or state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction or state.

About Osiris Therapeutics
Osiris Therapeutics, Inc. (NASDAQ:OSIR) is a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas. Osiris currently markets and sells Osteocel® for regenerating bone in orthopedic indications. Prochymal™ is entering Phase III clinical trials and is the only stem cell therapeutic currently designated by FDA as both an Orphan Drug and Fast Track product. The Company’s pipeline of internally developed biologic drug candidates under evaluation also includes Chondrogen™ for regenerating cartilage in the knee, and Provacel™, for repairing heart tissue following a heart attack. Osiris is a fully integrated company, having developed stem cell capabilities in research and development, manufacturing, marketing and distribution. Osiris has developed an extensive intellectual property portfolio to protect the company’s technology in the United States and a number of foreign countries including 45 U.S. and 153 foreign patents owned or licensed.

For additional information, please contact Lisa Rodemann at 410.522.5005, extension 610.

Osiris Therapeutics, Inc.
2001 Aliceanna Street
Baltimore, Maryland 21231
Ph 410.522.5005
Fax [phone]
www.Osiris.com

[akummermehr [wO]]

...hiermit ist der Thread wieder eröffnet.

Mit freundlichen Grüßen, Andrea Kummermehr

[Charly_2]

Osiris Therapeutics Soars 14% On News (OSIR)

Business | siribiz | June 18, 2012 05:28 pm
More Sharing ServicesShare | Share on google Share on facebook Share on twitter Share on email

NEW YORK, June 18, 2012 (MESHPRESS) – U.S. stocks opened with modest fall on Monday as Greek-election results were overcome by concern over rising government bond yields in Spain. Earlier, stock futures were trading higher, however the euro turned lower against the dollar.

Osiris Therapeutics Inc (NASDAQ OSIR) soared 13.83% to $10.45. The 52-week range for the stock is $4.12 and $11.58. The Company has received consent from New Zealand to market its first-in-class stem cell therapy Prochymal. Prochymal is for the treatment of acute graft-vs-host disease in children. Osiris submitted a New Medicine Application to Medsafe in May of 2011 and was granted Priority Review in June of 2011. The Company expects that Prochymal will be commercially available in New Zealand later this year.

Kurs aktuell bei $10.30

[Gilbertus]

Interessante Einschätzung;

http://seekingalpha.com/article/678401-5-pharma-companies-i-…